Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $0.8t | $871.50 | -1.4% | 2.7M |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.6t | $225.21 | -1.0% | 7.9M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $377.0b | $198.28 | -0.2% | 7.5M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $300.7b | $188.23 | -0.8% | 2.1M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $292.0b | $110.34 | -1.4% | 9.2M |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $188.1b | $340.17 | -1.3% | 2.6M |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $169.2b | $127.72 | -2.1% | 8.2M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $122.0b | $57.89 | -1.4% | 10.7M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $79.2b | $744.61 | -0.9% | 603.2K |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $26.5b | $204.50 | +0.4% | 1.1M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $19.9b | $49.65 | +0.5% | 4.1M |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $19.1b | $48.68 | -4.0% | 6.1M |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $18.4b | $131.79 | -2.6% | 4.8M |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $18.0b | $95.70 | +1.1% | 2.1M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $11.3b | $88.55 | -0.4% | 1.5M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $11.3b | $201.26 | +2.4% | 1.3M |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $10.9b | $44.65 | -0.6% | 2.1M |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $7.6b | $104.04 | -0.4% | 491.4K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $7.4b | $64.49 | -1.3% | 1.3M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $6.8b | $7.30 | -1.9% | 11.1M |
 ACLX | Arcellx, Inc. Common Stock | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $6.7b | $115.06 | +0.0% | 16.1M |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.7b | $36.60 | -0.6% | 1.0M |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $5.4b | $66.87 | -2.6% | 758.0K |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.2b | $125.75 | +3.9% | 995.4K |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $4.8b | $19.94 | -1.3% | 1.3M |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $4.8b | $84.12 | -0.2% | 980.1K |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.6b | $15.82 | -26.4% | 22.6M |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $4.1b | $46.20 | +0.3% | 646.7K |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $3.2b | $81.87 | -3.4% | 232.5K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.8b | $29.46 | -4.1% | 961.4K |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $2.7b | $26.36 | +2.3% | 2.7M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.6b | $44.89 | +1.4% | 629.4K |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $2.6b | $24.95 | -2.2% | 1.1M |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $2.4b | $33.87 | -1.3% | 618.2K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 IMNM | Immunome, Inc. | Radiopharmaceuticals & ADCsTargeted Therapy & Precision Oncology | $2.2b | $23.50 | -0.3% | 1.1M |
 SNDX | Syndax Pharmaceuticals, Inc. | Immunotherapy & Immuno-Oncology | $2.0b | $21.00 | -1.9% | 1.3M |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $2.0b | $14.22 | +0.6% | 1.1M |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $1.9b | $54.94 | +1.0% | 447.7K |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $1.9b | $86.78 | -5.4% | 1.6M |
 TYRA | Tyra Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.9b | $36.92 | -1.8% | 882.8K |
 ZYME | Zymeworks Inc. | Targeted Therapy & Precision Oncology | $1.8b | $28.55 | +1.6% | 950.2K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.7b | $14.94 | -1.3% | 4.1M |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $1.5b | $16.49 | -1.1% | 615.6K |
 DMRA | Damora Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.5b | $25.56 | +3.3% | 267.3K |
 NUVB | Nuvation Bio Inc. | Targeted Therapy & Precision Oncology | $1.4b | $4.59 | -6.1% | 6.6M |
 NTLA | Intellia Therapeutics, Inc | Cell & Gene Therapy for Cancer | $1.4b | $13.03 | -4.4% | 27.1M |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $1.4b | $3.42 | -0.6% | 10.3M |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.4b | $10.21 | -0.3% | 1.4M |
 VIR | Vir Biotechnology, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.4b | $10.64 | +2.7% | 1.8M |